The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Celldex
Consulting or Advisory Role - Celldex
Research Funding - Agensys (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600).
 
Anthony B. El-Khoueiry
Honoraria - Bayer; Bristol-Myers Squibb; Merrimack; Novartis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; CytomX Therapeutics
Speakers' Bureau - Merrimack
 
Omid Hamid
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Genentech; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genentech (Inst); Immunocore (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Rinat (Inst); Roche (Inst)
 
John A. Thompson
No Relationships to Disclose
 
Willeke Ros
No Relationships to Disclose
 
Ferry Eskens
Consulting or Advisory Role - Daiichi Sankyo; Ipsen; Merck; Novartis; Pfizer
Travel, Accommodations, Expenses - Daiichi Sankyo; Ipsen; Roche
 
Toshihiko Doi
Consulting or Advisory Role - Amgen; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Novartis
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Siwen Hu-Lieskovan
Consulting or Advisory Role - Amgen (Inst); Emergent BioSolutions (Inst); Merck (Inst); Novartis (Inst); Vaccinex (Inst)
Research Funding - Bristol-Myers Squibb; Genentech; Neon Therapeutics; Pfizer; Plexxikon
 
Jeffrey Chou
Employment - Amgen; Pfizer
Stock and Other Ownership Interests - Amgen
 
Ken Liao
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Bishu J Ganguly
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Catherine Fleener
Employment - Pfizer
Stock and Other Ownership Interests - Bristol-Myers Squibb; Pfizer
 
Tenshang Joh
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Research Funding - Pfizer
 
Adi Diab
Consulting or Advisory Role - Celgene; CureVac; Nektar
Research Funding - Celgene (Inst); Idera (Inst); Nektar (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Nektar